News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Napo Pharmaceuticals, Inc. Release: New Treatment Presented for Chronic Diarrhea in HIV/AIDS Patients


3/9/2012 6:32:52 AM

SAN FRANCISCO--(BUSINESS WIRE)--A poster describing the results of the final Phase 3 clinical trial for crofelemer, a drug being developed for the indication of chronic diarrhea in people living with HIV/AIDS on anti-retro viral therapy (CRO-HIV), was presented in Seattle this afternoon. The presentation took place as part of a session titled, “ADVENT Trial: Crofelemer for the Treatment of Secretory Diarrhea in HIV+ Individuals” during the Conference on Retroviruses and Opportunistic Infections (CROI). Crofelemer is a product of San Francisco-based Napo Pharmaceuticals, Inc.

Read at BioSpace.com


comments powered by Disqus
   
Diarrhea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES